Legend Biotech Corporation (NASDAQ: LEGN), a leading chimeric antigen receptor (CAR) T cell therapy specialist based in China, has announced plans to establish a state-of-the-art research and development center in Philadelphia, Pennsylvania. The new 31,000 sq. ft. facility, expected to open in the third quarter of 2025, will focus on the development of next-generation cell therapies.
The company, which already employs over 1,200 people in the US, plans to staff the new site with an additional 55 full-time employees. This expansion complements Legend’s existing research and development presence in the US, including another facility in New Jersey. Legend highlighted the strategic advantage of the Philadelphia location due to its proximity to top academic institutions at the forefront of medical science research.- Flcube.com
